Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21369405 | 0.93 | CYP19A1 (0.49) | CYP19A1TDP1LMNACYP1A2CYP3A4 | |
| SCHEMBL19728957 | 0.90 | TDP1 (0.45) | CYP19A1TDP1LMNACYP1A2CYP3A4 | |
| SCHEMBL13194995 | 0.89 | CYP19A1 (0.52) | CYP19A1TDP1LMNACYP1A2CYP3A4 | |
| SCHEMBL18671414 | 0.88 | CNR1 (0.48) | CYP19A1TDP1LMNACYP1A2CYP3A4 | |
| SCHEMBL18479712 | 0.87 | CNR1 (0.50) | CYP19A1TDP1LMNACYP1A2CYP3A4 | |
| SCHEMBL22024917 | 0.86 | TDP1 (0.45) | CYP19A1TDP1LMNACYP1A2CYP3A4 | |
| SCHEMBL23665185 | 0.85 | CNR1 (0.48) | CYP19A1TDP1LMNACYP1A2CYP3A4 | |
| SCHEMBL18852714 | 0.83 | CNR1 (0.50) | CYP19A1TDP1LMNACYP1A2CYP3A4 | |
| SCHEMBL21419383 | 0.82 | TDP1 (0.47) | CYP19A1TDP1LMNACYP1A2CYP3A4 | |
| SCHEMBL18427184 | 0.81 | CYP19A1 (0.49) | CYP19A1TDP1LMNACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | ENANTA PHARMACEUTICALS, INC. | 2023-10-31 | — | — | US | disclosed |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-15 | — | — | US | disclosed |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20230062815-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-20230011652-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-01-12 | — | — | US | disclosed |
| US-20220401430-A1 | ALLOSTERIC MODULATORS OF THE MU OPIOID RECEPTOR | Chiromics, LLC | 2022-12-22 | — | — | US | disclosed |
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | XIAMEN UNIVERSITY (CN) | 2022-06-07 | — | — | US | disclosed |
| US-10407424-B2 | Naphthyridines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190194136-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | UNIV NEW YORK (US) | 2019-06-27 | — | — | US | disclosed |
| US-10189016-B2 | Nano-to-nano Fe/ppm Pd catalysis of cross-coupling reactions in water | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-01-29 | — | — | US | disclosed |
| US-9919064-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170341069-A1 | NANO-TO-NANO FE/PPM Pd CATALYSIS OF CROSS-COUPLING REACTIONS IN WATER | UNIV CALIFORNIA (US) | 2017-11-30 | — | — | US | disclosed |
| US-9713651-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170202984-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170151353-A9 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-06-01 | — | — | US | disclosed |
| US-9555138-B2 | — | — | 2017-01-31 | — | — | US | disclosed |
| US-20140243292-A1 | SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062815-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CYP19A1 2422/4885TDP1 1532/4885LMNA 1699/4885 |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | CYP19A1 3074/4885TDP1 2831/4885LMNA 4383/4885 |
| US-20170151353-A9 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | TNNI3, FABP3, TNNT2 | CYP19A1 3523/4885TDP1 1575/4885LMNA 1473/4885 |
| US-20220401430-A1 | ALLOSTERIC MODULATORS OF THE MU OPIOID RECEPTOR | OPRM1, OPRK1, OPRD1 | CYP19A1 2873/4885TDP1 3598/4885LMNA 4854/4885 |
| US-10407424-B2 | Naphthyridines as inhibitors of HPK1 | NEK1, NEK5, NEK11 | CYP19A1 3624/4885TDP1 1150/4885LMNA 2129/4885 |
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | HAVCR2, HDGF, HCCS | CYP19A1 1126/4885TDP1 4244/4885LMNA 2254/4885 |
| US-20140243292-A1 | SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | RYR2, CACNA1E, SLC8B1 | CYP19A1 3222/4885TDP1 3058/4885LMNA 2019/4885 |
| US-20230011652-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CYP19A1 2444/4885TDP1 1513/4885LMNA 1651/4885 |
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CYP19A1 2625/4885TDP1 1146/4885LMNA 2052/4885 |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | CYP19A1 2422/4885TDP1 1532/4885LMNA 1699/4885 |
| US-10189016-B2 | Nano-to-nano Fe/ppm Pd catalysis of cross-coupling reactions in water | SOD1, MPO, TFRC | CYP19A1 4510/4885TDP1 4667/4885LMNA 4670/4885 |
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, RORB | CYP19A1 20/4885TDP1 2934/4885LMNA 4325/4885 |
| US-20190194136-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | AGER, HMGB1, GPR119 | CYP19A1 1092/4885TDP1 1686/4885LMNA 793/4885 |
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | PIKFYVE, PIK3CA, PIK3C2A | CYP19A1 2879/4885TDP1 1069/4885LMNA 3498/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | CYP19A1 2584/4885TDP1 725/4885LMNA 3212/4885 |
| US-20170341069-A1 | NANO-TO-NANO FE/PPM Pd CATALYSIS OF CROSS-COUPLING REACTIONS IN WATER | SOD1, MPO, TFRC | CYP19A1 4510/4885TDP1 4667/4885LMNA 4670/4885 |
| US-20170202984-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | CYP19A1 2722/4885TDP1 777/4885LMNA 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.